Last updated: September 2, 2026
Sitravatinib is an investigational, oral, multi-kinase inhibitor developed by Mirati Therapeutics and now controlled by Bristol Myers Squibb following its 2023 acquisition of Mirati. The drug has no FDA approval, no commercial revenue, and no Orange Book-listed product. Its lead development strategy was combination treatment with nivolumab in advanced non-small cell lung cancer and renal cell carcinoma.
The principal value driver failed to mature. The Phase 3 SAPPHIRE trial in previously treated non-squamous NSCLC did not meet its overall-survival objective, and the program lost strategic priority. The base-case commercial forecast is therefore zero through 2030 unless Bristol Myers Squibb restarts development or a third party acquires the asset for a narrower oncology indication.
What is sitravatinib and how does it work?
Sitravatinib, formerly known as MGCD516, is an oral small-molecule tyrosine kinase inhibitor. It inhibits a broad group of receptor tyrosine kinases involved in tumor growth, angiogenesis, immune suppression, and resistance to immunotherapy.
Reported targets include:
| Target group |
Examples |
Development rationale |
| TAM kinases |
TYRO3, AXL, MER |
Reduce immunosuppressive signaling and tumor-cell survival |
| VEGF pathway |
VEGFR2 and related kinases |
Inhibit angiogenesis |
| MET pathway |
MET |
Address tumor growth and acquired resistance |
| RET and other kinases |
RET, KIT, PDGFR and related targets |
Broaden activity across molecularly diverse tumors |
Sitravatinib was designed to modify the tumor microenvironment and improve response to immune checkpoint inhibition. The main combination partner was nivolumab, the PD-1 inhibitor marketed by Bristol Myers Squibb as Opdivo.
What is the current FDA status of sitravatinib?
Sitravatinib is not FDA approved as of the latest public regulatory records. The FDA has not granted it a New Drug Application approval, and no commercial dosage form is listed in the Orange Book.
| Regulatory item |
Status |
| FDA approval |
None |
| Approved indication |
None |
| Orange Book listing |
None |
| FDA-approved label |
None |
| Approved generic pathway |
None |
| Breakthrough Therapy designation |
No publicly established approval outcome |
| Fast Track designation |
Development-related designations were reported, but no approval followed |
| Commercial launch |
None |
Sitravatinib has been studied under investigational new-drug protocols. Trial participation does not establish efficacy, approval eligibility, or commercial launch timing.
What happened in the Phase 3 SAPPHIRE trial?
SAPPHIRE was the pivotal Phase 3 study of sitravatinib plus nivolumab in patients with advanced or metastatic non-squamous NSCLC after progression on platinum-based chemotherapy and a PD-1 or PD-L1 inhibitor.
ClinicalTrials.gov identifies the study as NCT03906071. The trial compared sitravatinib plus nivolumab with docetaxel, a standard chemotherapy comparator.
| SAPPHIRE characteristic |
Detail |
| Trial number |
NCT03906071 |
| Phase |
Phase 3 |
| Disease |
Advanced or metastatic non-squamous NSCLC |
| Prior therapy |
Platinum chemotherapy and immune checkpoint therapy |
| Experimental arm |
Sitravatinib plus nivolumab |
| Comparator |
Docetaxel |
| Primary endpoint |
Overall survival |
| Sponsor |
Mirati Therapeutics |
| Strategic owner after acquisition |
Bristol Myers Squibb |
Mirati reported that SAPPHIRE failed to demonstrate a statistically significant overall-survival improvement. The result removed the most direct path to registration in a large commercial indication. The failure also weakened the rationale for the broader sitravatinib-plus-nivolumab platform.
What other clinical development has sitravatinib completed?
Sitravatinib generated earlier signals in renal cell carcinoma, NSCLC, and other advanced solid tumors, primarily in combination with nivolumab.
Renal cell carcinoma
The renal cell carcinoma program focused on patients who had progressed after prior immune checkpoint therapy and antiangiogenic treatment. The rationale was competitive with approved combinations and later-line agents such as cabozantinib, axitinib, lenvatinib, and everolimus.
Early clinical data supported further study, but the program did not produce an approved indication. The competitive standard of care also changed rapidly as pembrolizumab, lenvatinib, cabozantinib, and other regimens expanded their positions in kidney cancer.
Non-small cell lung cancer
NSCLC was the largest potential market for sitravatinib. The drug was tested in patients with limited remaining treatment options after immunotherapy and chemotherapy. This population has high unmet need, but it is difficult to commercialize because of short treatment duration, heterogeneous biology, and intense competition among targeted and immuno-oncology products.
The negative SAPPHIRE result substantially reduced the probability of a broad NSCLC launch.
Other solid tumors
Sitravatinib has been evaluated in exploratory studies involving tumors such as melanoma, urothelial cancer, and other advanced solid malignancies. These studies have not established a registration-quality indication.
When did Bristol Myers Squibb acquire sitravatinib?
Bristol Myers Squibb agreed to acquire Mirati Therapeutics in 2023. The transaction gave Bristol Myers Squibb control of Mirati’s marketed and pipeline assets, including sitravatinib.
The acquisition was structured with upfront and contingent consideration. Mirati’s approved product adagrasib, marketed as Krazati, was the principal commercial asset. Sitravatinib was a pipeline asset rather than an approved revenue contributor.
The acquisition changed sitravatinib’s development context in three ways:
- Bristol Myers Squibb already markets nivolumab, the principal combination partner.
- SAPPHIRE’s failure reduced the expected return from continued investment.
- Bristol Myers Squibb has competing oncology programs and must allocate capital across a large pipeline.
Public company disclosures after the acquisition did not establish a new pivotal development plan for sitravatinib.
Has sitravatinib development been discontinued?
The development program lost momentum after the SAPPHIRE failure. The drug has not advanced to FDA filing or commercial launch.
A formal discontinuation statement should be distinguished from a lack of active development. Public trial records and company pipeline disclosures are the relevant indicators. The central commercial program has not produced an approval, and no new late-stage registration strategy has been established publicly.
The practical assessment is:
| Development question |
Assessment |
| Active pivotal program |
No established public program |
| Completed pivotal readout |
SAPPHIRE failed its primary survival objective |
| FDA filing |
None |
| Launch preparation |
None publicly established |
| Probability of near-term launch |
Very low |
| Potential for clinical restart |
Possible but commercially unattractive without a new efficacy signal |
What patents protect sitravatinib?
Sitravatinib is protected by composition-of-matter and related small-molecule patent families originating from its discovery and development programs. Rights were transferred or licensed through the MacroGenics and Mirati development chain and later came under Bristol Myers Squibb control through the Mirati acquisition.
The public FDA Orange Book does not list sitravatinib because the drug has no approved product. Orange Book patent listings therefore do not apply.
Patent analysis should separate three categories:
| Patent category |
Commercial relevance |
| Composition of matter |
Core protection for the active molecule and close analogues |
| Pharmaceutical composition and formulation |
Potential protection for tablets, excipients, salt forms, or solid-state characteristics |
| Method of use |
Potential protection for treatment combinations, patient populations, biomarkers, or dosing schedules |
No issued patent number should be treated as an FDA-listed barrier because sitravatinib has no approved reference product. Generic applicants cannot currently submit an Abbreviated New Drug Application referencing sitravatinib as an approved product.
What formulation patents protect sitravatinib?
Public development materials establish oral administration but do not establish a marketed formulation or an FDA-recognized formulation patent estate. Any tablet, capsule, salt, polymorph, particle-size, or manufacturing claims would matter only if the program reached approval or if a competing developer pursued the asset independently.
What method-of-use patents cover sitravatinib combinations?
The principal method-of-use concept is treatment with sitravatinib plus nivolumab in advanced solid tumors, including NSCLC and renal cell carcinoma. Such claims can be commercially useful when a combination is approved, but their value is limited when the underlying clinical trial fails.
What is the generic entry risk for sitravatinib?
There is no immediate generic entry risk because sitravatinib has no approved reference drug and no commercial market.
If sitravatinib were approved in the future, entry risk would depend on:
- Remaining composition-of-matter patent life.
- Validity of method-of-use and formulation claims.
- Whether the approved label supports a Paragraph IV challenge.
- The availability of non-infringing uses.
- The commercial size of the indication.
- The extent of regulatory exclusivity.
A future ANDA applicant could challenge listed patents through a Paragraph IV certification, but no such pathway is currently active because the product has no Orange Book listing.
What litigation or settlement agreements affect sitravatinib?
No major public patent litigation or generic settlement involving sitravatinib has become a material market event. The drug has no approved reference listed drug, no public Paragraph IV litigation profile, and no established launch settlement.
The primary legal event affecting the asset is corporate ownership through the Mirati acquisition, not patent enforcement.
How strong is the sitravatinib patent estate?
The underlying composition-of-matter estate likely provides the strongest protection because it covers the active chemical entity. Its commercial value is limited by the absence of approval and the failure of the lead Phase 3 trial.
Patent strength and asset value are separate measures:
| Factor |
Assessment |
| Chemical entity protection |
Potentially meaningful |
| Regulatory exclusivity |
None because there is no approval |
| Orange Book leverage |
None |
| Formulation value |
Unproven |
| Method-of-use value |
Reduced by failed pivotal efficacy |
| Freedom-to-operate risk |
Requires claim-by-claim review |
| Commercial enforceability |
No current marketed product to protect |
A strong composition patent cannot compensate for inadequate clinical efficacy. For sitravatinib, clinical and regulatory risk dominates patent risk.
What is the market size for sitravatinib?
Sitravatinib has no current market size because it has no sales. The addressable markets considered during development were advanced NSCLC and renal cell carcinoma, both multibillion-dollar global drug categories with established immune-oncology and tyrosine kinase competition.
The relevant commercial opportunity was the post-immunotherapy treatment segment rather than the entire cancer market. That segment is smaller, more fragmented, and subject to rapid treatment changes.
Scenario-based market projection
| Scenario |
2026-2030 outcome |
Estimated annual sitravatinib sales |
| Base case |
No restart; no approval |
$0 |
| Limited restart |
One narrow indication pursued, but no approval |
$0-$25 million |
| Successful niche approval |
Approval in a selected later-line solid-tumor population |
$50-$200 million peak |
| Broad approval |
Positive new pivotal data and approval in NSCLC or RCC |
$200-$500 million peak |
| Platform success |
Multiple indications and sustained nivolumab combination use |
Above $500 million, low probability |
The base case is zero through 2030. A relaunch would require new prospective evidence, a defined biomarker or patient-selection strategy, and a commercial rationale strong enough to compete against approved agents.
How does sitravatinib compare with competing drugs?
Sitravatinib competes with approved therapies that already have clinical guidelines, reimbursement pathways, and physician familiarity.
| Drug |
Main class |
Relevant markets |
Commercial position |
| Cabozantinib |
Multikinase inhibitor |
RCC, liver cancer, thyroid cancer |
Established later-line oncology product |
| Lenvatinib |
Multikinase inhibitor |
RCC combination, thyroid cancer, endometrial cancer |
Strong combination and multi-indication position |
| Axitinib |
VEGFR inhibitor |
RCC |
Approved and familiar targeted option |
| Docetaxel |
Cytotoxic chemotherapy |
NSCLC and other tumors |
Established comparator and low-cost option |
| Nivolumab |
PD-1 inhibitor |
Multiple cancers |
Potential combination partner, but not enough to rescue failed efficacy |
| Sitravatinib |
Investigational multikinase inhibitor |
NSCLC, RCC, other solid tumors |
No approval or commercial position |
Sitravatinib’s proposed differentiation was its combination of angiogenic and immune-modulating kinase activity. The SAPPHIRE failure weakened that differentiation relative to approved therapies.
What licensing deals involve sitravatinib?
Sitravatinib originated from MacroGenics and was licensed to Mirati Therapeutics. Mirati developed the program under the MGCD516 and sitravatinib names. Bristol Myers Squibb later obtained control through its acquisition of Mirati.
The licensing and ownership chain is therefore:
- MacroGenics: original discovery and rights holder.
- Mirati Therapeutics: development and clinical-stage rights holder.
- Bristol Myers Squibb: current corporate owner through the Mirati acquisition.
The asset has not generated a public commercial royalty stream because there is no approved sitravatinib product.
What is the likely generic launch scenario?
No generic launch is expected in the near term.
A future launch would require all of the following:
- A successful clinical restart.
- A new pivotal trial or convincing indication-specific evidence.
- FDA approval.
- Orange Book patent listings.
- A defined commercial indication.
- Sufficient remaining exclusivity to support investment.
The most plausible hypothetical path would be a narrow, biomarker-defined combination indication, not a broad post-immunotherapy NSCLC label. Even that path would face competition from established kinase inhibitors and checkpoint-based combinations.
Key Takeaways
- Sitravatinib is an investigational oral multikinase inhibitor now controlled by Bristol Myers Squibb.
- The drug has no FDA approval, no Orange Book listing, and no revenue.
- The Phase 3 SAPPHIRE trial in previously treated non-squamous NSCLC failed its overall-survival objective.
- Development in renal cell carcinoma and other solid tumors has not produced a registration path.
- Composition-of-matter patents may provide underlying chemical protection, but there is no current FDA-listed patent barrier.
- No material Paragraph IV litigation, generic settlement, or commercial launch dispute affects the asset.
- The base-case 2026-2030 revenue forecast is $0.
- A narrow approval could produce roughly $50 million to $200 million in peak annual sales, but the probability is low.
- Sitravatinib compares unfavorably with approved competitors such as cabozantinib, lenvatinib, axitinib, and docetaxel because those products have established labels and reimbursement.
FAQs
Could sitravatinib be revived for a biomarker-selected cancer population?
Yes, but revival would require a new clinical rationale. A biomarker-selected program targeting AXL, MET, RET, or immune-resistant tumors could reduce development scope, but no publicly established registration plan currently supports that strategy.
Is sitravatinib the same drug as MGCD516?
Yes. MGCD516 was the earlier development code for sitravatinib.
Can a generic manufacturer challenge sitravatinib patents now?
No meaningful ANDA-based challenge is currently available because sitravatinib has no FDA-approved reference product and no Orange Book listing.
Does nivolumab ownership improve sitravatinib’s commercial prospects?
It provides control over the combination partner, but it does not resolve sitravatinib’s efficacy problem. The failed SAPPHIRE outcome remains the principal development barrier.
What would make sitravatinib commercially investable again?
A new randomized efficacy signal, a defined responder population, manageable safety, patent life sufficient to support launch, and a treatment setting where approved kinase inhibitors do not already dominate.
References
-
Bristol Myers Squibb. (2023). Bristol Myers Squibb completes acquisition of Mirati Therapeutics. Bristol Myers Squibb.
-
ClinicalTrials.gov. (n.d.). A study of sitravatinib in combination with nivolumab versus docetaxel in patients with advanced or metastatic non-squamous non-small cell lung cancer: NCT03906071. U.S. National Library of Medicine.
-
Mirati Therapeutics, Inc. (2023). Annual report on Form 10-K for the fiscal year ended December 31, 2022. U.S. Securities and Exchange Commission.
-
U.S. Food and Drug Administration. (n.d.). Approved drug products with therapeutic equivalence evaluations: Orange Book. FDA.
-
Mirati Therapeutics, Inc. (2021). Mirati announces top-line results from Phase 3 SAPPHIRE study of sitravatinib in combination with nivolumab in patients with advanced non-squamous NSCLC. Mirati Therapeutics.